KRAS G12D-IN-29 is a selective inhibitor targeting the KRAS G12D mutant, known for its oral bioavailability. This compound effectively disrupts downstream signaling pathways associated with KRAS G12D, leading to a reduction in tumor cell proliferation. KRAS G12D-IN-29 shows potential for research applications focused on cancers driven by the KRAS G12D mutation, including pancreatic, lung, and colorectal cancers.
KRAS G12D-IN-29 is a selective inhibitor targeting the KRAS G12D mutant, known for its oral bioavailability. This compound effectively disrupts downstream signaling pathways associated with KRAS G12D, leading to a reduction in tumor cell proliferation. KRAS G12D-IN-29 shows potential for research applications focused on cancers driven by the KRAS G12D mutation, including pancreatic, lung, and colorectal cancers.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
